浙江医学
浙江醫學
절강의학
ZHEJIANG MEDICAL JOURNAL
2014年
9期
736-738
,共3页
结肠癌%CD151%整合素α3%免疫组化法
結腸癌%CD151%整閤素α3%免疫組化法
결장암%CD151%정합소α3%면역조화법
Colorectal carcinoma%CD151%Integrinα3%Immunohistochemistry
目的探讨CD151和整合素α3在结肠癌中的表达及临床意义。方法采用免疫组化SP法检测40例结肠炎组织、96例结肠癌组织中CD151及整合素α3的表达，并分析其相关性。结果结肠炎组织和结肠癌组织中CD151表达阳性率分别为0、88.5%；有淋巴结转移组和无淋巴结转移组中CD151表达阳性率分别为100％、63.3%；远处转移组和无远处转移组中CD151表达阳性率分别为100％、78.0%，差异均有统计学意义（均P＜0.05）；在结肠炎组织和结肠癌中整合素α3表达阳性率分别为0、87.5%；有淋巴结转移组和无淋巴结转移组表达阳性率分别为100％、60.0%；远处转移组和无远处转移组中表达阳性率分别为100％、76.0%，差异均有统计学意义（均P＜0.05）。CD151和整合素α3的表达阳性率在结肠癌患者的年龄、性别、肿瘤大小、组织学分型及分化程度中的差异均无统计学意义（均P＞0.05），而在有无淋巴结转移和远处转移中的差异有统计学意义（P＜0.05）。结论CD151和整合素α3的高表达与结肠癌的发生和转移有关，检测CD151和整合素α3的表达可能为结肠癌的诊断、预后判断及治疗提供参考依据。
目的探討CD151和整閤素α3在結腸癌中的錶達及臨床意義。方法採用免疫組化SP法檢測40例結腸炎組織、96例結腸癌組織中CD151及整閤素α3的錶達，併分析其相關性。結果結腸炎組織和結腸癌組織中CD151錶達暘性率分彆為0、88.5%；有淋巴結轉移組和無淋巴結轉移組中CD151錶達暘性率分彆為100％、63.3%；遠處轉移組和無遠處轉移組中CD151錶達暘性率分彆為100％、78.0%，差異均有統計學意義（均P＜0.05）；在結腸炎組織和結腸癌中整閤素α3錶達暘性率分彆為0、87.5%；有淋巴結轉移組和無淋巴結轉移組錶達暘性率分彆為100％、60.0%；遠處轉移組和無遠處轉移組中錶達暘性率分彆為100％、76.0%，差異均有統計學意義（均P＜0.05）。CD151和整閤素α3的錶達暘性率在結腸癌患者的年齡、性彆、腫瘤大小、組織學分型及分化程度中的差異均無統計學意義（均P＞0.05），而在有無淋巴結轉移和遠處轉移中的差異有統計學意義（P＜0.05）。結論CD151和整閤素α3的高錶達與結腸癌的髮生和轉移有關，檢測CD151和整閤素α3的錶達可能為結腸癌的診斷、預後判斷及治療提供參攷依據。
목적탐토CD151화정합소α3재결장암중적표체급림상의의。방법채용면역조화SP법검측40례결장염조직、96례결장암조직중CD151급정합소α3적표체，병분석기상관성。결과결장염조직화결장암조직중CD151표체양성솔분별위0、88.5%；유림파결전이조화무림파결전이조중CD151표체양성솔분별위100％、63.3%；원처전이조화무원처전이조중CD151표체양성솔분별위100％、78.0%，차이균유통계학의의（균P＜0.05）；재결장염조직화결장암중정합소α3표체양성솔분별위0、87.5%；유림파결전이조화무림파결전이조표체양성솔분별위100％、60.0%；원처전이조화무원처전이조중표체양성솔분별위100％、76.0%，차이균유통계학의의（균P＜0.05）。CD151화정합소α3적표체양성솔재결장암환자적년령、성별、종류대소、조직학분형급분화정도중적차이균무통계학의의（균P＞0.05），이재유무림파결전이화원처전이중적차이유통계학의의（P＜0.05）。결론CD151화정합소α3적고표체여결장암적발생화전이유관，검측CD151화정합소α3적표체가능위결장암적진단、예후판단급치료제공삼고의거。
Objective To investigate the expression and clinical significance of CD151 and integrinα3 in colorectal car-cinoma and its clinicopathological significance. Methods The expressions of CD151 and integrinα3 were examined by using immunohistochemistry in tissue sections from 40 cases of colonitis and 96 cases of colorectal carcinoma. Results The positive rates of CD151 in colonitis and colorectal carcinoma tissues were 0.0%(0/40) and 88.5%(85/96), respectively;in colorectal carci-noma with lymph node metastasis and those without lymph node metastasis were 100.0%(66/66) and 63.3%(19/30), respectively;in colorectal carcinoma with distant metastasis and those without distant metastasis were 100.0%(46/46) and 78.0%(39/50), re-spectively (al P<0.05). The positive rates of integrinα3 in colonitis and colorectal carcinoma tissue were 0.0%(0/40) and 87.5%(84/96), respectively;in colorectal carcinoma with lymph node metastasis and those without lymph node metastasis were 100.0%(66/66) and 60.0%(18/30), respectively;in colorectal carcinoma with distant metastasis and those withour distant metastasis were 100.0%(46/46) and 76.0%(38/50), respectively (al P<0.05). The expression of CD 151 and integrinα3 was not correlated with age, gender, tumor size, pathological types and differentiation of colorectal carcinoma (al P>0.05), while closely correlated with lymph node metastasis and distant metastasis. Conclusion Detection of CD151 and integrinα3 may be of value in diagnosis, prognosis and treatment monitoring of colorectal carcinoma.
